Bpifrance

Mycophyto is a French company founded in 2016, co-created by microbiologist Justine Lipuma and Senior Research Engineer Christine Poncet-Doise. Based in Mougins, the company focuses on developing biological solutions aimed at revitalizing soil and enhancing plant growth. Mycophyto specializes in analyzing soil to identify indigenous fungi and pathogens beneficial for plant development. By isolating, multiplying, and inoculating mycorrhizae, the company provides customized products and support services for new agricultural systems. This innovative approach allows plant researchers to cultivate crops and herbs using natural soil microorganisms, minimizing reliance on chemical fertilizers and promoting sustainable agricultural practices.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

LISAqua operates a sustainable aquaculture farm focused on breeding prawns using an innovative process that avoids antibiotics and pollution. The company's farming methodology incorporates advanced predictive modeling technology to monitor and anticipate changes in pond water conditions. By employing the perm aquaculture method, which integrates complementary species to create a closed marine ecosystem, LISAqua aims to provide responsibly sourced seafood to consumers and communities. This approach not only enhances environmental sustainability but also promotes healthy seafood production.

Cell-Easy SAS operates as a stem cell contract development and manufacturing organization (CDMO) that provides ready-to-inject adipose derived allogeneic stem cells for preclinical and clinical development projects. The company’s allogeneic production process allows using the biological material of a healthy donor to help thousands of patients. The company was incorporated in 2017 and is based in Toulouse, France.

Developer a biotechnology platform intended to improve the quality of life of patients. The company's platform specializes in developing an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy with cancer therapy and senescence, enabling patients to have proper health and treatment.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Lysogene S.A. is a biotechnology company based in Neuilly-sur-Seine, France, focused on the research and clinical development of gene therapy for neurodegenerative disorders. Founded in 2009, the company is advancing several clinical programs, including LYS-SAF302, currently in Phase II/III trials for the treatment of mucopolysaccharidosis type IIIA, and LYS-GM101, which is in Phase I/II trials for GM1 gangliosidosis. Lysogene is also engaged in a collaborative research effort with the Weizmann Institute of Science to develop a novel AAV gene therapy approach targeting neuronopathic Gaucher disease, Parkinson's disease, and other conditions. The company aims to enhance the health outcomes of patients suffering from life-threatening, incurable disorders by utilizing AAV vectors that effectively deliver genetic material to the central nervous system.

Provepharm life Solutions is a truly unique life sciences research and pharma company, dedicated to a new era of discovery. We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. As PROVEPHARM LIFE SOLUTIONS, we are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care.

LISAqua operates a sustainable aquaculture farm focused on breeding prawns using an innovative process that avoids antibiotics and pollution. The company's farming methodology incorporates advanced predictive modeling technology to monitor and anticipate changes in pond water conditions. By employing the perm aquaculture method, which integrates complementary species to create a closed marine ecosystem, LISAqua aims to provide responsibly sourced seafood to consumers and communities. This approach not only enhances environmental sustainability but also promotes healthy seafood production.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Seekyo SAS is a biotechnology company based in Poitiers, France, established in 2018. The company specializes in developing innovative treatment options for cancer patients, focusing on the creation of smart molecular systems. These systems are designed to transport potent anticancer agents selectively, targeting the microenvironment of solid tumors while minimizing harm to healthy tissues. Seekyo's approach utilizes advanced technologies such as antibody drug conjugates and small molecule drug conjugates, which specifically recognize cancer cell surface markers and tumor microenvironment characteristics. This allows for the controlled release of therapeutic agents directly at the tumor site, enhancing treatment efficacy and reducing adverse effects. By prioritizing the safety and effectiveness of chemotherapy, Seekyo aims to improve the overall treatment experience for cancer patients.

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.

Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.